Regulation of c-jun expression during induction of monocytic differentiation by okadaic acid

Cell Growth Differ. 1992 Jul;3(7):391-9.

Abstract

The present work has examined the effects of okadaic acid, an inhibitor of type 1 and 2A protein phosphatases, on the regulation of c-jun expression during monocytic differentiation of U-937 leukemia cells. The results demonstrate that okadaic acid treatment is associated with induction of a differentiated monocyte phenotype characterized by: (a) growth arrest; (b) increases in Mac-1 cell surface antigen expression; (c) down-regulation of c-myc transcripts; and (d) induction of tumor necrosis factor gene expression. This induction of monocytic differentiation was associated with transient increases in c-jun mRNA levels, which were maximal at 6 h. Similar effects were obtained for the c-fos gene. Run-on analysis demonstrated detectable levels of c-jun transcription in U-937 cells and that this rate is increased approximately 40-fold following okadaic acid exposure. c-jun mRNA levels were superinduced in cells treated with both okadaic acid and cycloheximide, whereas inhibition of protein synthesis had little, if any, effect on okadaic acid-induced c-jun transcription. The half-life of c-jun mRNA was similar (45-50 min) in both untreated and okadaic acid-induced cells. In contrast, treatment with both okadaic acid and cycloheximide was associated with stabilization (t 1/2 = 90 min) of c-jun transcripts. Taken together, these findings indicate that the induction of c-jun transcription by okadaic acid is controlled primarily by a transcriptional mechanism. Since previous studies have demonstrated that the c-jun gene is autoinduced by Jun/AP-1, we also studied transcription of c-jun promoter (positions -132/+170)-reporter gene constructs with and without a mutated AP-1 element.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • Cell Differentiation / drug effects
  • Cell Division / drug effects
  • Cycloheximide / pharmacology
  • Dactinomycin / pharmacology
  • Ethers, Cyclic / pharmacology*
  • Gene Expression Regulation, Leukemic / drug effects*
  • Genes, jun / drug effects*
  • Humans
  • Isoquinolines / pharmacology
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Male
  • Monocytes / drug effects*
  • Monocytes / pathology
  • Neoplasm Proteins / biosynthesis*
  • Neoplasm Proteins / genetics
  • Neoplastic Stem Cells / drug effects*
  • Neoplastic Stem Cells / pathology
  • Okadaic Acid
  • Piperazines / pharmacology
  • Protein Kinase C / antagonists & inhibitors
  • Proto-Oncogene Proteins c-fos / biosynthesis
  • Proto-Oncogene Proteins c-fos / genetics
  • Proto-Oncogene Proteins c-jun / biosynthesis*
  • Proto-Oncogene Proteins c-jun / genetics
  • RNA Processing, Post-Transcriptional / drug effects
  • RNA, Messenger / analysis
  • RNA, Neoplasm / analysis
  • Signal Transduction / drug effects
  • Tetradecanoylphorbol Acetate / pharmacology
  • Transcription, Genetic / drug effects
  • Tumor Cells, Cultured / drug effects

Substances

  • Ethers, Cyclic
  • Isoquinolines
  • Neoplasm Proteins
  • Piperazines
  • Proto-Oncogene Proteins c-fos
  • Proto-Oncogene Proteins c-jun
  • RNA, Messenger
  • RNA, Neoplasm
  • Dactinomycin
  • Okadaic Acid
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • Cycloheximide
  • Protein Kinase C
  • Tetradecanoylphorbol Acetate